Theranostics with simultaneous diagnosis and therapy functions are potential to greatly
improve the therapeutic efficacy and reduce side effects. Fluorescence imaging has …

Platinum-based anticancer drugs dominate the chemotherapy field for several cancers, but
problems such as systemic toxicity and acquired resistance for some primary tumors hamper …

The development of multidrug resistance (MDR) to chemotherapy remains a major
challenge in the treatment of cancer. Resistance exists against every effective anticancer …

The platinum (Pt) drugs cisplatin and carboplatin are heavily employed in chemotherapy
regimens; however, similar to other classes of drugs, a number of intrinsic and acquired …

Cisplatin, or cis-diamminedichloridoplatinum (II) cis-[PtCl 2 (NH 3) 2], is a platinum-based
anticancer drug largely used for the treatment of various types of cancers, including …

The era of platinum-based anticancer drugs was heralded by the clinical introduction of
cisplatin (1), a square-planar platinum (II) complex whose antitumor properties were first …

When cisplatin was first synthesized, over 150 years ago, inorganic chemistry was in its
infancy and no one would have foreseen a role in medicine. Some 120 years later …

Drug discovery and development is a high-risk, expensive endeavor and it commonly takes
about 10− 15 years to obtain marketing approval from project inception. 1 Research efforts …

Two mononuclear fluorophore-labeled copper (II) complexes [Cu (nip)(acac)]+(2) and [Cu
(nip) 2] 2+(3), where fluorophore is 2-(naphthalen-1-yl)-1 H-imidazo [4, 5-f][1, 10] …

Cisplatin is a chemotherapeutic drug commonly used in clinics. However, acquired
resistance confines its application in chemotherapeutics. To overcome the acquired …